Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, 270 Rama VI Rd., Ratchathewi, Bangkok, Thailand.
Nephrology Division, Department of Medicine, Bhumibol Adulyadej Hospital, Bangkok, Thailand.
Health Qual Life Outcomes. 2020 Jun 18;18(1):191. doi: 10.1186/s12955-020-01449-2.
End-stage renal disease (ESRD) leads to renal replacement therapy and certainly has an impact on patients' health-related quality of life (HRQoL). This study aimed to review and compare the HRQoL between peritoneal dialysis (PD) and hemodialysis (HD) patients using the 36-Item Short Form Health Survey (SF-36), EuroQoL-5-dimension (EQ-5D) and the Kidney Disease Quality of Life Instrument (KDQOL).
Systematic review was conducted by identify relevant studies through MEDLINE and SCOPUS up to April 2017. Studies were eligible with following criteria: studied in ESRD patients, compare any pair of renal replacement modalities, and reported HRQoL. The unstandardized mean differences (USMD) of HRQoL among modalities were calculated and pooled using a random-effect models if heterogeneity was present, otherwise a fixed-effect model was applied.
A total of twenty-one studies were included with 29,000 participants. Of them, mean age and percent male were 48.1 years and 45.1, respectively. The pooled USMD (95% CI) of SF-36 between PD and HD (base) were 1.86 (0.47, 3.24) and 0.42 (- 1.99, 2.82) for mental component and physical component summary scores, respectively. For EQ-5D, the pooled USMD of utility and visual analogue scale (VAS) score were 0.02 (- 0.06, 0.10) and 3.56 (1.73, 5.39), respectively. The pooled USMD of KDQOL were 9.67 (5.67, 13.68), 6.71 (- 5.92, 19.32) 6.30 (- 0.41, 12.18), 2.35 (- 4.35, 9.04), 2.10 (0.07, 4.13), and 1.21 (- 2.98, 5.40) for burden of kidney disease, work status, effects of kidney disease, quality of social interaction, symptoms, and cognitive function.
Patients with chronic kidney disease (CKD) stage 5 or ESRD treated with PD had better generic HRQoL measured by SF-36 and EQ-5D than HD patients. In addition, PD had higher specific HRQoL by KDQOL than HD patients in subdomain of physical functioning, role limitations due to emotional problems, effects and burden of kidney disease.
终末期肾病(ESRD)导致肾脏替代治疗,肯定会对患者的健康相关生活质量(HRQoL)产生影响。本研究旨在使用 36 项简短健康调查(SF-36)、欧洲五维健康量表(EQ-5D)和肾脏病生活质量量表(KDQOL)对腹膜透析(PD)和血液透析(HD)患者的 HRQoL 进行回顾和比较。
通过 MEDLINE 和 SCOPUS 系统检索截至 2017 年 4 月的相关研究,以确定符合条件的研究。符合条件的研究包括:ESRD 患者、比较任何两种肾脏替代治疗方式以及报告 HRQoL 的研究。如果存在异质性,则使用随机效应模型计算和汇总各治疗方式间 HRQoL 的未标准化均数差(USMD),否则应用固定效应模型。
共纳入 21 项研究,共 29000 名参与者。其中,平均年龄和男性比例分别为 48.1 岁和 45.1%。PD 和 HD(基础)组 SF-36 心理成分和生理成分综合评分的 USMD(95%CI)分别为 1.86(0.47,3.24)和 0.42(-1.99,2.82)。对于 EQ-5D,效用和视觉模拟量表(VAS)评分的 USMD 分别为 0.02(-0.06,0.10)和 3.56(1.73,5.39)。KDQOL 的 USMD 分别为 9.67(5.67,13.68)、6.71(-5.92,19.32)、6.30(-0.41,12.18)、2.35(-4.35,9.04)、2.10(0.07,4.13)和 1.21(-2.98,5.40),分别代表肾脏疾病负担、工作状态、肾脏疾病影响、社会互动质量、症状和认知功能。
接受 PD 治疗的慢性肾脏病(CKD)5 期或 ESRD 患者的一般 HRQoL 优于 HD 患者,SF-36 和 EQ-5D 可衡量。此外,PD 在生理功能、因情绪问题导致的角色限制、肾脏疾病的影响和负担等亚领域的特定 HRQoL 高于 HD 患者。